US3917654A - Anti-inflammatory substituted benzofuran - Google Patents

Anti-inflammatory substituted benzofuran Download PDF

Info

Publication number
US3917654A
US3917654A US368174A US36817473A US3917654A US 3917654 A US3917654 A US 3917654A US 368174 A US368174 A US 368174A US 36817473 A US36817473 A US 36817473A US 3917654 A US3917654 A US 3917654A
Authority
US
United States
Prior art keywords
acid
mixture
phenyl
compounds
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US368174A
Inventor
Francis J Petracek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIKU LAB Inc
RIKU LABORATORIES Inc
Original Assignee
RIKU LAB Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RIKU LAB Inc filed Critical RIKU LAB Inc
Priority to US368174A priority Critical patent/US3917654A/en
Application granted granted Critical
Publication of US3917654A publication Critical patent/US3917654A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Definitions

  • R is hydrogen, or lower alkyl; R and R are hydrogen or when taken together form a double bond, provided that when R and R together form a double bond, R may be halogen and when R is halogen, the
  • the group is preferably in the 7 position.
  • Other preferred groups of the compounds of the invention are those in which R and R together form a double bond, and in which R is hydrogen or methyl and R is hydrogen.
  • the substituents are preferably lower alkyl, lower alkoxy or halogen, most preferably halogen.
  • the compounds of the invention may be substituted on the benzo portion of the benzofuran ring in the 5, 6 or 7 positions. It is presently preferred that the group is at the 6 or 7 position.
  • the two Y groups (located at .the remaining positions) can be the .same or different.
  • At least one Y group is hydrogen, most pref- .For'mula', f
  • both are hydrogen.
  • one Y group is other than hydrogen, it is preferably lower alkyl, lower alkoxy or hydroxy.
  • p is zero or one and most preferably p is zero.
  • alkyl portion of substituents herein refers to groups containing one to four carbon atoms, which may have straight or branched chains. When such alkyl or substituted alkyl groups are present, groups of one carbon atom are preferred.
  • halogen means fluorine, chlorine or bromine, and fluorine and chlorine are preferred.
  • the carbon atom to which R is chemically bonded is an asymmetric carbon atom.
  • the compounds of the invention are generally present in the form of a racemic mixture.
  • the resolution of such racemates can be carried out by a vast number of known methods. For example, some racemic mixtures can be precipitated as eutectics instead of mixed crystals and can thus be quickly separated and in such cases can sometimes be selectively precipitated.
  • the more common method of chemical resolution is, however, greatly preferred.
  • diastereomers are formed from the racemic mixture by reaction with an optically active resolving agent. Thus, an optically active organic acid can be reacted with the -CI-I- 0H group.
  • the desired isomer of the free alcohol may be prepared by any one of the preceding described resolving methods, preferably working from the free alcohol as the starting material. Ester diastereomers of the alcohol may be formed with optically active acids.
  • the active form is generally the (d) form but absolute rotation and even the sign of rotation of the more active form can vary with substitution and compounds must be tested in biological assays to establish their relative activity.
  • testing in animals is carried out using various assays known to those skilled in the art, for example, the carrageenan or bradykinin induced rat foot edema test, the inhibition of ultraviolet-light-induced erythema test (guinea pig), the rat adjuvant arthritis assay, the Randall-Selitto assay, the phenylquinone writhing assay for analgetic activity and the like.
  • the compounds of this invention have a high degree of anti-inflammatory activity and are of value in the which are known to respond to treatment by drugs with anti-inflammatory activity.
  • the compounds of the invention have a useful degree of antipyretic and analgesic activity.
  • they are normally administered orally in tablets or capsules, the optimum dosage depending upon the particular compound being used and the type and severity of the condition being treated.
  • the compounds are preferably administered orally, other known methods of administration are contemplated as well, e.g. dermatomucosally (for example dermally, rectally, and the like) and parenterally, for example by subcutaneous injection, intramuscular injection, intravenous injection and the like. Ocular administration is also included.
  • Suitable forms for oral administration include liquids (such as four percent acacia suspensions), tablets (which may contain anhydrous lactose, microcrystalline cellulose, modified starch, calcium stearate and talc, as well as other conventional compounding agents together with the active anti-inflammatory agent) and capsules.
  • suitable carriers for topical application include creams, gels, tapes and the like. Liquid formulations, such as solutions or suspensions of the active ingredient in inert carriers, are contemplated for dosage by injection.
  • Compounds of the invention are active in one or more of the standard assays.
  • Preferred compounds have a therapeutic ratio greater than 10.
  • the compounds of the invention are prepared by multistep synthetic sequences. The most convenient of these start with substituted phenols and form substituted benzofuran derivatives. The substituted benzofuran derivatives are then reactedto obtain the aliphatic side chain on the benzo ring. These skilled in the art will recognize that many variations of these sequences exist. The following discussion describes some of the useful processes for obtaining the compounds. The processes are represented graphically in the accompanying drawings.
  • Process A is represented by FIG. 1 wherein W is bromine, chlorine, iodine or methyl, Q is hydrogen or lower alkyl and Ar is as defined hereinabove.
  • step (1) the reactants are generally known to the art, equimolar amounts of the reactants, or an excess of the phenol are reacted in the presence of a base, generally a weak inorganic base such as an alkali metal carbonate.
  • a base generally a weak inorganic base such as an alkali metal carbonate.
  • a solvent is used, for example glyme, tetrahydrofuran, ethanol, pyridine and the like.
  • An inert atmosphere may be used.
  • the reaction is carried out at 50 to the reflux temperature.
  • the compound of formula II is isolated by conventional methods such as extraction or elution chromatography.
  • step (2) the compounds of formula II are cyclized by heating in polyphosphoric acid.
  • the novel product compounds of formula III are easily separated and isolated by dilution of the reaction mixture with water and filtration or extraction.
  • ProcessB is represented by FIG. 2 wherein W, Ar and Alkyl are as defined hereinabove and steps 1) and (2) are essentially the same as steps l) and (2) of Process A,
  • the reaction of step (1) uses generally known reactants.
  • Process C is represented by FIG. 3 wherein Hal is chlorine, bromine or iodine and Ar is as defined hereinabove.
  • Step (I) reacts one mole of a known haloacetic acid, particularly chloracetic acid, with one mole of a known halophenol in the presence of two moles of strong base such as sodium hydroxide.
  • the halophenoxyacetic acid product is readily isolated, or reacted further without isolation.
  • step (2) the halophenoxyacetic acid is heated strongly with a pre-reacted phosphorus pentoxideethanol mixture to effect cyclization and dehydration to a coumaran-3-one.
  • the product is readily isolated by conventional methods.
  • the coumaran-3-one is reacted in step (3) with an aryl Grignard reagent or ArLi using the methods and techniques well-known to the art.
  • the product is readily isolated.
  • Process D is represented by FIG. 4 wherein W, Alkyl and Ar are as defined hereinabove.
  • step (I) The reactants of step (I) are known compounds, readily cyclized in base such as sodium ethoxide in ethanol to the corresponding benzofurans (VI).
  • the compounds of formula VI are isolated by extraction.
  • step (2) the hydrolysis of the ester to the acid is carried out under acidic or basic conditions.
  • W is methyl
  • hydrolysis is preferably preceded by bromination of the methyl group with N-bromosuccinimide under free-radical conditions such as are known to the art, followed by reaction with an alkali metal cyanide to give a cyanomethyl derivative.
  • Step (3) decarboxylation, is carried out by any of the well-known methods employed in the art, for example heating in quinoline in the presence of a copper catalyst.
  • Process E is represented by FIG. 5 wherein R Ar and Alkyl are as defined hereinabove and Y" must be hydrogen.
  • step (1 a phenoxyacetophenone is formed as previously described in Process A, step (1).
  • step (2) the cyclization is carried out as described in Process A, step (2) to give the novel intermediate VIII. Cyclization may occur at either of the positions Y", and when these positions are non-equivalent two different isomeric products are formed. These isomers are separated by conventional methods such as elution chromatography, vapor phase chromatography, fractional crystallization, and the like.
  • the intermediates of formula III, IV, V, VI and VII all contain the benzofuran nucleus with an aryl substituent at the'3 position. These intermediates are then used in further synthetic sequences wherein the objective is to provide compounds which also include the radical.
  • the compounds of formula VIII are compounds which may be hydrolyzed, under acidic or basic conditions, to provide other compounds substituted by the group Furthermore, compounds of formula VIII may be transesterified using methods known to the art such as acidic or basic catalysis.
  • the compounds of formula VIII may be converted to carboxylic acid halides by reaction with the usual reagents such as thionyl chloride and phosphorus pentachloride.
  • the acyl halides can then be converted to products of the invention as described hereinafter.
  • Process F is represented by FIG. 6 wherein Hal and Ar are as defined hereinabove.
  • Step I may be carried out by any of the well-known methods for preparing Grignard reagents; tetrahydrofuran is a preferred solvent.
  • Step (2) may be carried out by a standard Grignard reaction with formaldehyde, with subsequent acidification to the alcohol.
  • Step (3) requires displacement of the hydroxyl by a halide by any of the well-known methods of the art; for example reaction with a hydrohalogen acid, a phosphorus acid or thionyl halide, or conversion to the mesylate or tosylate.
  • the reaction is preferably carried out in an inert solvent (for example benzene, toluene, xylene and the like) with thionyl chloride at any suitable temperature, but especially in benzene at reflux temperature until the reaction is substantially complete.
  • an inert solvent for example benzene, toluene, xylene and the like
  • step (4) The displacement of the halide with a cyanide by any of the well-known methods of the art is the reaction of step (4).
  • Suitable inorganic cyanides for example sodium cyanide, potassium cyanide and the like, are reacted in an inert solvent, such as dimethylsulfoxide, dimethoxyfuran, acetone, aqueous alcohol and the like.
  • an inert solvent such as dimethylsulfoxide, dimethoxyfuran, acetone, aqueous alcohol and the like.
  • the reaction is carried out in an acetoneethanol-water mixture with potassium cyanide at any suitable temperature, for example at the reflux temperature of the reaction mixture until the reaction is substantially complete.
  • step (5) the reaction is hydrolysis of the nitrile by any of the variety of the methods well-known to the art, that is acidic, or basic hydrolysis, preferably basic hydrolysis with an alkali metal hydroxide in ethanol.
  • Process G is represented by FIG. 7 wherein Hal, Ar and Alkyl are as above.
  • step (1) the Grignard reagent is reacted with an alpha keto ester, preferably ethyl pyruvate under any of the well-known Grignard condensation type reaction conditions.
  • step (2) hydrolysis is accomplished by any means well-known to the art.
  • Step (3) is carried out by any dehydration procedure well-known to the art.
  • Step (4) is catalytic reduction by methods wellknown to the art such as reduction over a catalyst, for example palladium, palladium on carbon, platinum, Raney nickel, platinum oxide and the like preferably under moderate hydrogen pressure (5 to 60 pounds) in an inert solvent such as lower alkanols, aromatic compounds, tetrahydrofuran, acetic acid, dioxane and the like at any suitable temperature, C. to reflux temperature of the system, preferably at room temperature 'until the reaction is substantially complete.
  • a catalyst for example palladium, palladium on carbon, platinum, Raney nickel, platinum oxide and the like preferably under moderate hydrogen pressure (5 to 60 pounds) in an inert solvent such as lower alkanols, aromatic compounds, tetrahydrofuran, acetic acid, dioxane and the like at any suitable temperature, C. to reflux temperature of the system, preferably at room temperature 'until the reaction is substantially complete.
  • Process H is represented by FIG. 8 wherein Hal, Alkyl and Ar are as defined hereinabove.
  • step (1) the benzofuran is reacted with a halogenating agent.
  • a halogenating agent Presently preferred is N-bromosuccinimide.
  • Free radical conditions which promote side chain halogenation are required, for example cobalt stearate and tertiary-butyl hydroperoxide may be used as a catalyst combination, and a strong source of visible light is commonly useful.
  • Step (2) displacement of the halide with a cyanide, is carried out as described in step (4), Process F.
  • Step (3) hydrolysis of the ester, is carried out by methods well-known to the art.
  • Step (4) simultaneous hydrolysis of the ester and the nitrile is carried out by vigorous hydrolysis with an al kali metal hydroxide in ethanol.
  • Step (5) selective decarboxylation, is carried out by heating in a guinolinepyridine mixture until about one mole of carbon dioxide evolved.
  • Step (6) dicarboxylation, is carried out as described in step (3), Process D.
  • Step (7) hydrolysis of the nitrile, is carried out by the methods described for step (5), Process F.
  • Process I is represented by FIG. 9 wherein R is methyl or ethyl and Alkyl and Ar are as defined hereinabove.
  • step l) the benzofuranacetic ester is converted to the reactive anionic intermediate by the action of a strong base such as sodamide, sodium hydride, lithium N,N-dialkylamide and the like.
  • a strong base such as sodamide, sodium hydride, lithium N,N-dialkylamide and the like.
  • the anionic intermediate is used without isolation for step (2).
  • step (2) alkylation is carried out by reaction with an alkyl halide such as methyl bromide, methyl iodide and ethyl bromide in an inert solvent such as benzene, diethyl ether, dimethyl sulfoxide and the like at any suitable temperature from C. to reflux temperature until the reaction is substantially complete.
  • an alkyl halide such as methyl bromide, methyl iodide and ethyl bromide
  • an inert solvent such as benzene, diethyl ether, dimethyl sulfoxide and the like
  • Process J is represented by FIG. 10 wherein Ar and R are as defined hereinabove.
  • step (1) the anionic intermediate is prepared as described in step (1), Process I.
  • step (2) the alkylation is carried out as described in step (2), Process I.
  • step (3) The hydrolysis of step (3) is carried out as described in step (5), Process F.
  • Process K is represented by FIG. 11 wherein Hal, Ar, Alkyl and R are so previously defined.
  • Step (1) is a Grignard reaction of a tert butyl alphahaloacetate, alpha-halopropionate or alpha-halobutyrate by methods well-known to the art.
  • Step (2) is the hydrolysis of the ester under known acidic or basic conditions.
  • Process L is represented by FIG. l2 wherein X is and R and Ar are as previously defined.
  • Process G step (4) but requiring a longer time or more vigorous condition.
  • An example is the use of a catalyst in a lower alkanol such as ethanol as the solvent.
  • Process M is represented by FIG. 13 wherein Hal and Ar are as previously defined [hereinabove.
  • step (I) the 2 position is halogenated with molecular halogen, preferably in an inert solvent. Chlorine and bromine are the preferred halogens.
  • Step (2) is side-chain halogenation effected as described in step (1), Process H.
  • Step (3) is carried out as described in step (4), Process F.
  • Step (4) is effected using the methods of step (5), Process F, preferably using acidic conditions.
  • Process N is represented by FIG. 14 wherein Hal, Ar and Alkyl are as previously defined hereinabove.
  • step l the dialkyl malonate is treated with strong base such as sodium hydride, then reacted with the halomethyl-3-arylbenzofuran, preferably in ethanol.
  • step (2) decarboxylation is readily effected by known methods, for example by heating the dry solid reactant to 150 to 200 C.-
  • Process 0 is represented by FIG. 15 wherein Hal and 1 Ar are as previously defined.
  • R and Y may not be halogen, and Ar is not substituted by halogen.
  • step (1 the benzofuran is reacted with cuprous cyanide in a solvent such as quinoline.
  • Step (2) is the reaction of the nitrile with methyl Grignard reagent.
  • step (3) the methyl ketone is converted to a carboxylic acid by, for example, the Willgerodt reaction.
  • Reaction (2) with diazomethane is a well-known reaction, discussed, for example in Organic Reactions, Volume 1, pages 38 ff. It has been found to proceed routinely in the class of compounds described by this invention.
  • a non-reactive solvent such as diethyl ether is used.
  • the diazoketone is a solid or liquid which may be isolated, but is generally not characterized. It is hydrolyzed as shown in step (3) under mildly acidic conditions in a suitable solvent, for example, dioxane. Suitable acids are organic or inorganic. Strong acids may be used, but they are generally dilute.
  • step (1) Phenacyl bromide (475 g., 2138 mole) is added to a mixture of 2-bromophenol (400 g., 2.3 mole) and potassium carbonate (470 g., 3.46 mole) in glyme (1600 ml) under a nitrogen atmosphere and the stirred mixture is heated to reflux temperature and maintained at reflux for eight hours. Some solid is present. The liquid portion is decanted, then evaporated to dryness. The residue after this evaporation is boiled in benzene and filtered.
  • the solid pot residue remaining after decanting is extracted with hot benzene several times, and these benzene extracts are combined with benzene filtrate. Hexane is added to the cooling benzene and a first crop collected. Partial evaporation gives a second crop.
  • the white solid is alpha-(2-bromophenoxy)acetophenone, m.p. l13.5115.
  • step (2) Polyphosphoric acid (4200 g.) and alpha-(2-bromophenoxyacetophenone (596 g., 2.05 mole) are heated and stirred well at about to internal temperature for four hours. The reaction mixture is then poured into stirred ice and water (about 8 1. total volume) to give a suspension of white solid. The solid is collected and washed with water, cold dilute sodium hydroxide solution and water until the wash is neutral. The solid is recrystalled from hexane to give white crystals of 7-bromo-3-phenylbenzofuran, m.p. 7274.
  • 7-methyl-3-phenylbenzofuran is obtained by cyclizing the required acetophenone at about 80 for one to two hours.
  • the optimum temperature and times vary with other substituents which may be present.
  • Additional intermediates of this type prepared by the general method of Process A illustrated by Example 1 and 2 include:
  • This oil is dissolved in three liters of 95% ethanol and 200 ml. of water and the mixture is heated to its reflux temperature. A solution of potassium hydroxide (232 g.) in water (400 ml.) is added over about one hour. The mixture is maintained at its reflux temperature for 3.5 hours. The mixture is then concentrated to about one-half of its volume and the residue is poured into cold water (1.5 1.). The cloudy mixture is extracted with diethyl ether (700 ml. portions).
  • the aqueous phase is poured into excess dilute hydrochloric acid and the mixture is cooled and acidified with hydrochloric acid.
  • the solid is collected by filtration and washed with several portions of hot water, then with petroleum ether.
  • the white solid is 2- hydroxy-2-[7-(3-phenyl)benzofuranyl]propionic acid, m.p. 1l2.5-ll7.
  • Another intermediate compound prepared by the general method illustrated by Example 3 is 2-hydroxy- 2-[7-(2-methyl-3-phenyl)benzofuranyHpropionic acid, m.p. l66-l66.5.
  • the hydroxy acid may be used directly as obtained for the next step.
  • EXAMPLE 4 Process G, step (3) Dry 2-hydroxy-2-[7-(3-phenyl)benzofuranyl]propionic acid (337 g., 1.19 mole) in toluene (3 1.) under a nitrogen atmosphere is treated with para-toluenesulfonic acid hydrate (70 g.) and hydroquinone (l g.) while refluxing to azeotropically remove water in a Dean-Start trap. After refluxing for three hours the reaction mixture is cooled, diluted with hexane and cooled by an ice bath. The solid product is collected by filtration washed with petroleum ether, then aqueous ethanol to give 2-[7-(3-phenyl)benzofuranyl]acrylic acid, m.p. l95.5-l98.5.
  • Additional intermediate compounds prepared by the general method illustrated in Example 4 include:
  • step (4) 2-[7-(3-Phenyl)benzofuranyl]]acrylic acid (40 g., 0.15 mole) is dissolved in warm ethanol (750 ml.) and palladium on charcoal (3 g.) is added. The reduction is carried out using hydrogen gas at 40 psi. initial pressure. The mixture is filtered, then evaporated in vacuo to dryness. The residue is dissolved in benzene (225 ml.) diluted with hexane and cooled. The solid is collected by filtration and again recrystallized from a hexane benzene mixture. The white crystals obtained are 2-[7-( 3-phenyl)benzofuranyl1propionic acid, m.p. l67.5l 68.5.
  • Paraformaldehyde (41.4 g., 1.38 mole) (dried over phosphorus pentoxide), is depolymerized at about 160 C. while passing the formaldehyde vapor into and over the stirred Grignard reaction mixture. The reaction is exothermic, causing a gentle reflux. Then reaction is complete, the mixture is concentrated to about onethird of its volume, then poured onto ice and water. Diethyl ether (50 ml.) is added, followed by slow addition of concentrated, cold 6N hydrochloric acid (250 ml.). The mixture is extracted with diethyl ether, the extracts are washed with water and saturated sodium chloride solution, dried and evaporated in vacuo to give an oil.
  • step (3) 3-(4-Fluorophenyl)-7-(hydroxymethyl)benzofuran (110 g., 0.45 mole) is dissolved in benzene (225 ml.) and added dropwise to refluxing thionyl chloride (110 ml.). Heating is continued until gas evolution is complete. Excess thionyl chloride and benzene are removed in vacuo, using additional benzene to aid in removing the thionyl chloride. The residue is a brown oil,
  • Additional intermediate compounds of the invention prepared according to the general method illustrated by Example 8 include: 7-cyanomethyl-3-phenylbenzofuran, m.p. 1101 1 1 7-cyanomethyl-3-(4-chlorophenyl)benzofuran, m.p. 106120
  • Process F step Potassium hydroxide (85%, 49 g.), 7-cyanomethyl-3- (4-fluorophenyl)benzofuran (48.8 g., 0.194 mole) and 95% ethanol (500 ml.) are mixed and heated at reflux temperature overnight under a nitrogen atmosphere. The mixture is then concentrated by evaporation in vacuo, diluted with water and extracted with diethyl ether.
  • the aqueous phase is filtered, then acidified by the slow addition of hydrochloric acid.
  • the solid is collected by filtration and recrystallized from aqueous ethanol (65%) with treatment with decolorizing charcoal, giving yellow crystals.
  • Another recrystallization from an ethanol-petroleum ether mixture (about 5:1) gives yellow crystals of 3-(4-fluorophenyl)-7-benzofuranacetic acid, m.p. 169-l70.
  • Additional intermediate compounds of the invention prepared by the general method illustrated by Example 9 include: 3-phenyl-7-benzofuranacetic acid, m.p. 143l44 3-phenyl-5-benzofuranacetic acid, m.p. 131.5l32 3-phenyl-7-(S-methoxybenzofuran)acetic acid, m.p. 16l162 3-phenyl-6-benzofuranacetic acid, m.p. 142-l44 3-phenyl-7-( S-methylbenzofuran )acetic acid, m.p.. 1 34135 (2-methyl-3-phenylbenzofuran )-6-acetic acid, m .p.
  • the 6-acetic acids were prepared by way of the es"- ters, Process E.
  • EXAMPLE 10 Process L 3-Phenyl-7-benzofuranacetic acid (2.5 g., 0.01 mole) is reduced with hydrogen gas using palladium on charcoal as catalyst and ethanol as solvent in a Brown hydrogenator. After the absorption of hydrogen stops, the reaction mixture is filtered, then the filtrate is evaporated in vacuo to a white solid. Recrystallization from a benzene-hexane mixture gives white crystals of 2,3-
  • Diethyl malonate (12.7 g., 0.079 mole) is dissolved in ethanol (40 ml.) and treated with sodium hydride (0.079 mole).
  • 7-Chloromethyl-3-phenylbenzofuran (10.0 g., 0.0396 mole) is added and the mixture is heated to its reflux temperature and maintained at reflux for ten hours.
  • Equal volumes of water and diethyl ether are added and the ether extracts are evaporated in vacuo.
  • the residue is dissolved in ethanol and potassium hydroxide (16 g.) is added and the mixture is heated on a steam bath. A yellow solid forms rapidly, but heating is continued overnight.
  • the solution is concentrated by evaporation in vacuo, then equal volumes of water and diethyl ether are added.
  • the ether layer is washed with water, dried then evaporated to dryness.
  • the residue is recrystallized from benzene to give 3- phenyl-7-benzofuranylmethylmalonic acid,
  • 3-Phenyl-7-benzofuranylmethylmalonic acid (1.8 g.) is heated to 180 dry, with an oil bath. Gas is evolved for about 10 minutes. The residue is recrystallized from 13 a mixture of benzene-methanol to give 3-[7-(3- phenyl)benzofuranyll-propionic acid, m.p. l6l.5-l62.5.
  • EXAMPLE l2 Process M, step (1) and (2) 7-Methyl-3-phenylbenzofuran is treated with an equimolar amount of bromine in carbon tetrachloride at room temperature until decolorized.
  • the mixture is concentrated to dryness to remove hydrobromic acid and redissolved in carbon tetrachloride.
  • To this solution is added an equimolar amount of N-bromosuccinimide and catalytic amounts (about one gram/mole of benzofuran) of cobalt stearate and tertiary-butyl hydroperoxide.
  • the mixture is heated to reflux temperature and maintained at reflux for two hours while shining a bright floodlight directly upon the reaction mixture.
  • EXAMPLE 16 A solution of 1.0 g. of 5-methoxy-3-phenyl-7-benzofuranacetic acid in 5 ml. of acetic acid and 1 ml. of 47% hydriodic acid is heated at reflux for 16 hours to obtain the corresponding S-hydroxy acid. It is isolated by precipitation with water, extraction into ether and then into sodium bicarbonate solution. Recrystallization from benzene gives 5-hydroxy -3-phenyl-7-benzofuranacetic acid, m.p. 197.5199.
  • EXAMPLE 17 By the procedures illustrated in Examples 12 and 6-9 and starting with a-bromo-4-dimethylaminoacetophenone respectively, one obtains: 3-(4-methylthiophenyl)-7-benzofuranacetic acid 3-(4-methylsulfinylphenyl)-7-benzofuranacetic acid 3-(4-methylsulfonylphenyl)-7-benzofuranacetic acid 3-(3-trifluoromethylphenyl)-7-benzofuranacetic acid 3-(4-dimethylaminophenyl)-7-benzofuranacetic acid.
  • the acid chloride (4.3 g., 14.8 mmole) is dissolved in diethyl ether (80 ml.) and added dropwise to a cold (about 0 C.) solution of diazomethane (45 mmole) in diethyl ether (100 ml.) over a period of 30 minutes.
  • the solution is stirred at 0 C. for two hours, then evaporated under vacuum.
  • the residue is a light yellow solid, 3-(4-fluorophenyl)-7-benzofuranacetyldiazomethane.
  • the infrared spectrum of the product is consistent with the assigned structure.
  • the substituted diazomethane is then dissolved in dioxane (80 ml.) and treated with 0.1N aqueous perchloric acid (40 ml.) while stirring at 6065 for 1.5 hours.'The mixture is evaporated under vacuum, then water is added and the mixture is again evaporated under vacuum. The white solid precipitate is separated by filtration and washed with water and petroleum ether. The solid is dissolved in diethyl ether and the solution is washed thrice with 50 ml. portions of 1N aqueous sodium carbonate and thrice with 50 ml. portions of saturated sodium chloride solution, then dried over anhydrous magnesium sulfate.
  • the acid chloride is dissolved in diethyl ether (50 m1.) and added dropwise to a stirred cold (about 0) solution of diazomethane (57 mmoles) in diethyl ether (125 ml.). After the addition the mixture is stirred for 0.5 hour at 0 and 0.5 hour at ambient temperature. The mixture is then evaporated under vacuum to alight yellow oil.
  • the infrared spectrum of the product, 2-[7- (3-phenyl)benzofuranyl)]propionyldiazomethane is consistent with the assigned structure.
  • the substituted diazomethane is then dissolved in dioxane (100 m1.) and treated with 0.5N aqueous perchloric acid (50 m1.)while stirring at about 65 C. for 0.75 hour.
  • the solution is evaporated under vacuum, and the residue is extracted with diethyl ether.
  • the ether extracts are washed thrice with ml. portions of 1N aqueous sodium carbonate, then the ether solution is filtered, then evaporated under vacuum to provide a light yellow oil.
  • the oil is chromatographed on a silica gel column, eluting with hexane, 50:50 hexane:- chloroform, chloroform and 50:50 chloroformtmethanol. Infrared spectral analysis of the fractions obtained shows that the later fractions are chiefly the desired product.
  • Two recrystallizations from ethanol:petroleum ether mixtures give white solid product, hy-
  • R is hydrogen.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

3-Phenyl benzofurans substituted at the 5, 6 or 7 position by a hydroxymethylketoalkyl group which are active anti-inflammatory agents.

Description

United States Petracek ANTI-INFLAMMATORY SUBSTITUTED BENZOFURAN [75] Inventor: Francis J. Petracek, Bloomington,
Minn.
[73] Assignee: Riker Laboratories, Inc.,
Northridge, Calif.
22 Filed: June 8, 1973 21 Appl. No.: 368,174
OTHER PUBLICATIONS Lundquist et al., Chem. Abstracts, (1972), V01. .87, 47537.
Primary Examiner.l0hn M. Ford Assistant Examiner-Bernard Dentz Attorney, Agent, or FirmAlexander, Sell, Steldt & DeLaHunt [57] ABSTRACT 3-Phenyl benzofurans substituted at the 5, 6 or 7 position by a hydroxymethylketoalkyl group which are active anti-inflammatory agents.
9 Claims, 34 Drawing Figures ANTI-INFLAMIVIATQRY SUBSTITUTED I BENZOFURAN This invention relates to 3-phenyl benzofurans substituted at the 5, 6 or 7 position by a hydroxymethylketoalkyl group which are active anti-inflammatory agents. 7 i g The invention also relates to methods of use of the compounds of the invention as anti-inflammatory and analgetic agents and to methods for the preparation of the compoundsof the invention.
DETAILED DESCRIPTION According to the present invention, there is provided a class of compounds of the formula wherein R is hydrogen, or lower alkyl; R and R are hydrogen or when taken together form a double bond, provided that when R and R together form a double bond, R may be halogen and when R is halogen, the
group is preferably in the 7 position. Other preferred groups of the compounds of the invention are those in which R and R together form a double bond, and in which R is hydrogen or methyl and R is hydrogen. When Ar is substituted, the substituents are preferably lower alkyl, lower alkoxy or halogen, most preferably halogen. The compounds of the invention may be substituted on the benzo portion of the benzofuran ring in the 5, 6 or 7 positions. It is presently preferred that the group is at the 6 or 7 position. The two Y groups (located at .the remaining positions) can be the .same or different.
Preferably at least one Y group is hydrogen, most pref- .For'mula', f
2 erably both are hydrogen. When one Y group is other than hydrogen, it is preferably lower alkyl, lower alkoxy or hydroxy. Preferably, p is zero or one and most preferably p is zero.
When the term lower is used 'to refer to the alkyl portion of substituents herein, it refers to groups containing one to four carbon atoms, which may have straight or branched chains. When such alkyl or substituted alkyl groups are present, groups of one carbon atom are preferred.
When halogen substituents are present in compounds of the invention, halogen means fluorine, chlorine or bromine, and fluorine and chlorine are preferred.
In compounds of the invention wherein R is hydro gen and R is not hydrogen, the carbon atom to which R is chemically bonded is an asymmetric carbon atom. In this case the compounds of the invention are generally present in the form of a racemic mixture. The resolution of such racemates can be carried out by a vast number of known methods. For example, some racemic mixtures can be precipitated as eutectics instead of mixed crystals and can thus be quickly separated and in such cases can sometimes be selectively precipitated. The more common method of chemical resolution is, however, greatly preferred. By this method diastereomers are formed from the racemic mixture by reaction with an optically active resolving agent. Thus, an optically active organic acid can be reacted with the -CI-I- 0H group. The difference in solubility between the diastereomers formed permits the selective crystallization of one form and regeneration of the opticallyactive acid from the mixture. There is, however, a third method of resolving which shows great promise. This method is one of the other forms of biochemical procedures using selective enzymatic reaction. Thus, the racemic alcohol compound can be subjected to as asymmetric oxidase which will by oxidation destroy one form, leaving the other form unchanged. Even more attractive is the use of a hydrolysase or esterase on a derivative of the racemic mixture to form preferentially one form of the alchol. Thus, esters of the alcohols can be subjected to an esterase which will selectively saponify one enantiomorph and leave the other unchanged.
When the free alcohol is resolved into (d) and (1) enantiomorphs, the anti-inflammatory activity is found to reside virtually completely in one isomer. The desired isomer of the free alcohol may be prepared by any one of the preceding described resolving methods, preferably working from the free alcohol as the starting material. Ester diastereomers of the alcohol may be formed with optically active acids.
The active form is generally the (d) form but absolute rotation and even the sign of rotation of the more active form can vary with substitution and compounds must be tested in biological assays to establish their relative activity.
In order to determine and assess the pharmacological activity of the compounds of the invention, testing in animals is carried out using various assays known to those skilled in the art, for example, the carrageenan or bradykinin induced rat foot edema test, the inhibition of ultraviolet-light-induced erythema test (guinea pig), the rat adjuvant arthritis assay, the Randall-Selitto assay, the phenylquinone writhing assay for analgetic activity and the like.
The compounds of this invention have a high degree of anti-inflammatory activity and are of value in the which are known to respond to treatment by drugs with anti-inflammatory activity. In addition, the compounds of the invention have a useful degree of antipyretic and analgesic activity. For these purposes they are normally administered orally in tablets or capsules, the optimum dosage depending upon the particular compound being used and the type and severity of the condition being treated. Although the compounds are preferably administered orally, other known methods of administration are contemplated as well, e.g. dermatomucosally (for example dermally, rectally, and the like) and parenterally, for example by subcutaneous injection, intramuscular injection, intravenous injection and the like. Ocular administration is also included. Dosages ordinarily fall within the range of about 1 to 500 mg./kg. of body weight of the mammal to be treated although oral dosages are not usually above 100 mg./kg. and injection dosages are not usually above 50 mg./kg. Suitable forms for oral administration include liquids (such as four percent acacia suspensions), tablets (which may contain anhydrous lactose, microcrystalline cellulose, modified starch, calcium stearate and talc, as well as other conventional compounding agents together with the active anti-inflammatory agent) and capsules. Suitable carriers for topical application include creams, gels, tapes and the like. Liquid formulations, such as solutions or suspensions of the active ingredient in inert carriers, are contemplated for dosage by injection.
Compounds of the invention are active in one or more of the standard assays. Preferred compounds have a therapeutic ratio greater than 10.
The compounds of the invention are prepared by multistep synthetic sequences. The most convenient of these start with substituted phenols and form substituted benzofuran derivatives. The substituted benzofuran derivatives are then reactedto obtain the aliphatic side chain on the benzo ring. These skilled in the art will recognize that many variations of these sequences exist. The following discussion describes some of the useful processes for obtaining the compounds. The processes are represented graphically in the accompanying drawings.
Process A is represented by FIG. 1 wherein W is bromine, chlorine, iodine or methyl, Q is hydrogen or lower alkyl and Ar is as defined hereinabove.
In step (1) the reactants are generally known to the art, equimolar amounts of the reactants, or an excess of the phenol are reacted in the presence of a base, generally a weak inorganic base such as an alkali metal carbonate. A solvent is used, for example glyme, tetrahydrofuran, ethanol, pyridine and the like. An inert atmosphere may be used. The reaction is carried out at 50 to the reflux temperature. The compound of formula II is isolated by conventional methods such as extraction or elution chromatography.
In step (2) the compounds of formula II are cyclized by heating in polyphosphoric acid. The novel product compounds of formula III are easily separated and isolated by dilution of the reaction mixture with water and filtration or extraction.
Rearrangement of Ar from ring position 3 to 2 can occur if care is not taken in the cyclization step when Q H. The structure of the product is verified by the ultraviolet absorption spectrum. 3-Phenyl derivatives have A max about 228 and 254, e about 25,000 and 13,000 respectively, while the 2-phenyl derivatives have A about 300 with an e of about 30,000.
ProcessB is represented by FIG. 2 wherein W, Ar and Alkyl are as defined hereinabove and steps 1) and (2) are essentially the same as steps l) and (2) of Process A, The reaction of step (1) uses generally known reactants. n
Process C is represented by FIG. 3 wherein Hal is chlorine, bromine or iodine and Ar is as defined hereinabove.
Step (I reacts one mole of a known haloacetic acid, particularly chloracetic acid, with one mole of a known halophenol in the presence of two moles of strong base such as sodium hydroxide. The halophenoxyacetic acid product is readily isolated, or reacted further without isolation.
In step (2) the halophenoxyacetic acid is heated strongly with a pre-reacted phosphorus pentoxideethanol mixture to effect cyclization and dehydration to a coumaran-3-one. The product is readily isolated by conventional methods.
The coumaran-3-one is reacted in step (3) with an aryl Grignard reagent or ArLi using the methods and techniques well-known to the art. The product is readily isolated.
Process D is represented by FIG. 4 wherein W, Alkyl and Ar are as defined hereinabove.
The reactants of step (I) are known compounds, readily cyclized in base such as sodium ethoxide in ethanol to the corresponding benzofurans (VI). The compounds of formula VI are isolated by extraction.
In step (2) the hydrolysis of the ester to the acid is carried out under acidic or basic conditions. Alternatively, if W is methyl, hydrolysis is preferably preceded by bromination of the methyl group with N-bromosuccinimide under free-radical conditions such as are known to the art, followed by reaction with an alkali metal cyanide to give a cyanomethyl derivative.
Step (3), decarboxylation, is carried out by any of the well-known methods employed in the art, for example heating in quinoline in the presence of a copper catalyst.
Process E is represented by FIG. 5 wherein R Ar and Alkyl are as defined hereinabove and Y" must be hydrogen.
In step (1 a phenoxyacetophenone is formed as previously described in Process A, step (1).
In step (2) the cyclization is carried out as described in Process A, step (2) to give the novel intermediate VIII. Cyclization may occur at either of the positions Y", and when these positions are non-equivalent two different isomeric products are formed. These isomers are separated by conventional methods such as elution chromatography, vapor phase chromatography, fractional crystallization, and the like.
The intermediates of formula III, IV, V, VI and VII all contain the benzofuran nucleus with an aryl substituent at the'3 position. These intermediates are then used in further synthetic sequences wherein the objective is to provide compounds which also include the radical The compounds of formula VIII are compounds which may be hydrolyzed, under acidic or basic conditions, to provide other compounds substituted by the group Furthermore, compounds of formula VIII may be transesterified using methods known to the art such as acidic or basic catalysis. The compounds of formula VIII may be converted to carboxylic acid halides by reaction with the usual reagents such as thionyl chloride and phosphorus pentachloride. The acyl halides can then be converted to products of the invention as described hereinafter.
The synthetic sequences whereby benzofuran intermediates are converted to intermediate carboxylic acids, are described further hereinbelow:
Process F is represented by FIG. 6 wherein Hal and Ar are as defined hereinabove.
Step I may be carried out by any of the well-known methods for preparing Grignard reagents; tetrahydrofuran is a preferred solvent.
Step (2) may be carried out by a standard Grignard reaction with formaldehyde, with subsequent acidification to the alcohol.
Step (3) requires displacement of the hydroxyl by a halide by any of the well-known methods of the art; for example reaction with a hydrohalogen acid, a phosphorus acid or thionyl halide, or conversion to the mesylate or tosylate. The reaction is preferably carried out in an inert solvent (for example benzene, toluene, xylene and the like) with thionyl chloride at any suitable temperature, but especially in benzene at reflux temperature until the reaction is substantially complete.
The displacement of the halide with a cyanide by any of the well-known methods of the art is the reaction of step (4). Suitable inorganic cyanides, for example sodium cyanide, potassium cyanide and the like, are reacted in an inert solvent, such as dimethylsulfoxide, dimethoxyfuran, acetone, aqueous alcohol and the like. As an example the reaction is carried out in an acetoneethanol-water mixture with potassium cyanide at any suitable temperature, for example at the reflux temperature of the reaction mixture until the reaction is substantially complete.
In step (5) the reaction is hydrolysis of the nitrile by any of the variety of the methods well-known to the art, that is acidic, or basic hydrolysis, preferably basic hydrolysis with an alkali metal hydroxide in ethanol.
Process G is represented by FIG. 7 wherein Hal, Ar and Alkyl are as above.
In step (1) the Grignard reagent is reacted with an alpha keto ester, preferably ethyl pyruvate under any of the well-known Grignard condensation type reaction conditions.
In step (2) hydrolysis is accomplished by any means well-known to the art.
Step (3) is carried out by any dehydration procedure well-known to the art.
Step (4) is catalytic reduction by methods wellknown to the art such as reduction over a catalyst, for example palladium, palladium on carbon, platinum, Raney nickel, platinum oxide and the like preferably under moderate hydrogen pressure (5 to 60 pounds) in an inert solvent such as lower alkanols, aromatic compounds, tetrahydrofuran, acetic acid, dioxane and the like at any suitable temperature, C. to reflux temperature of the system, preferably at room temperature 'until the reaction is substantially complete.
Process H is represented by FIG. 8 wherein Hal, Alkyl and Ar are as defined hereinabove.
In step (1) the benzofuran is reacted with a halogenating agent. Presently preferred is N-bromosuccinimide. Free radical conditions which promote side chain halogenation are required, for example cobalt stearate and tertiary-butyl hydroperoxide may be used as a catalyst combination, and a strong source of visible light is commonly useful.
Step (2), displacement of the halide with a cyanide, is carried out as described in step (4), Process F.
Step (3), hydrolysis of the ester, is carried out by methods well-known to the art.
Step (4), simultaneous hydrolysis of the ester and the nitrile is carried out by vigorous hydrolysis with an al kali metal hydroxide in ethanol.
Step (5), selective decarboxylation, is carried out by heating in a guinolinepyridine mixture until about one mole of carbon dioxide evolved.
Step (6), dicarboxylation, is carried out as described in step (3), Process D.
Step (7), hydrolysis of the nitrile, is carried out by the methods described for step (5), Process F.
Process I is represented by FIG. 9 wherein R is methyl or ethyl and Alkyl and Ar are as defined hereinabove.
In step l) the benzofuranacetic ester is converted to the reactive anionic intermediate by the action of a strong base such as sodamide, sodium hydride, lithium N,N-dialkylamide and the like. The anionic intermediate is used without isolation for step (2).
In step (2) alkylation is carried out by reaction with an alkyl halide such as methyl bromide, methyl iodide and ethyl bromide in an inert solvent such as benzene, diethyl ether, dimethyl sulfoxide and the like at any suitable temperature from C. to reflux temperature until the reaction is substantially complete.
Process J is represented by FIG. 10 wherein Ar and R are as defined hereinabove.
In step (1) the anionic intermediate is prepared as described in step (1), Process I.
In step (2), the alkylation is carried out as described in step (2), Process I.
The hydrolysis of step (3) is carried out as described in step (5), Process F.
Process K is represented by FIG. 11 wherein Hal, Ar, Alkyl and R are so previously defined.
Step (1) is a Grignard reaction of a tert butyl alphahaloacetate, alpha-halopropionate or alpha-halobutyrate by methods well-known to the art.
Step (2) is the hydrolysis of the ester under known acidic or basic conditions.
Process L is represented by FIG. l2 wherein X is and R and Ar are as previously defined.
In this process reduction is carried out as in Process G, step (4) but requiring a longer time or more vigorous condition. An example is the use of a catalyst in a lower alkanol such as ethanol as the solvent.
Process M is represented by FIG. 13 wherein Hal and Ar are as previously defined [hereinabove.
In step (I) the 2 position is halogenated with molecular halogen, preferably in an inert solvent. Chlorine and bromine are the preferred halogens.
Step (2) is side-chain halogenation effected as described in step (1), Process H.
Step (3) is carried out as described in step (4), Process F.
Step (4) is effected using the methods of step (5), Process F, preferably using acidic conditions.
Process N is represented by FIG. 14 wherein Hal, Ar and Alkyl are as previously defined hereinabove.
In step l) the dialkyl malonate is treated with strong base such as sodium hydride, then reacted with the halomethyl-3-arylbenzofuran, preferably in ethanol.
In step (2) decarboxylation is readily effected by known methods, for example by heating the dry solid reactant to 150 to 200 C.-
Process 0 is represented by FIG. 15 wherein Hal and 1 Ar are as previously defined.
When this method is used R and Y may not be halogen, and Ar is not substituted by halogen.
In step (1 the benzofuran is reacted with cuprous cyanide in a solvent such as quinoline.
Step (2) is the reaction of the nitrile with methyl Grignard reagent.
In step (3) the methyl ketone is converted to a carboxylic acid by, for example, the Willgerodt reaction.
The intermediate acids are conveniently converted to the final compounds of the invention of formula I through the sequence shown in FIG. 16. wherein Z is Reaction (1) uses any of the well-known methods for the preparation of acid chlorides. Reaction with thionyl chloride has been found to be a very convenient route for obtaining the acid chloride.
Reaction (2) with diazomethane is a well-known reaction, discussed, for example in Organic Reactions, Volume 1, pages 38 ff. It has been found to proceed routinely in the class of compounds described by this invention. A non-reactive solvent such as diethyl ether is used. The diazoketone is a solid or liquid which may be isolated, but is generally not characterized. It is hydrolyzed as shown in step (3) under mildly acidic conditions in a suitable solvent, for example, dioxane. Suitable acids are organic or inorganic. Strong acids may be used, but they are generally dilute.
Compounds of the invention wherein Y is not hydrogen are prepared by the processes A through 0 described hereinabove by incorporating the substituents in the starting phenols, or by appropriate reaction of the intermediates as would be apparent to one skilled in the art. Other transformations of one substituent to another on the structure of formula I, constitute additional processes for the preparations of these compounds, i.e. the Ys are transformed to another set of Ys and/or Ar is converted to another Ar and/or R to another R by methods familiar to those skilled in the art. Examples include reactions as halogenation, alkylation of hydroxy groups and amines and oxidation of sulfides to sulfoxides. Y
The following examples are given for the purpose of further illustrating the procedures useful for obtaining the compounds of the invention but are not intended,
in any way, to be limiting on the scope thereof. Thus, other processes and known and may be applied by those skilled in the art to obtain the compounds of this invention.
All melting points in the examples are uncorrected. The temperatures are given in degrees Centigrade and the pressures in millimeters of mercury.
EXAMPLE 1 Process A, step (1) Phenacyl bromide (475 g., 2138 mole) is added to a mixture of 2-bromophenol (400 g., 2.3 mole) and potassium carbonate (470 g., 3.46 mole) in glyme (1600 ml) under a nitrogen atmosphere and the stirred mixture is heated to reflux temperature and maintained at reflux for eight hours. Some solid is present. The liquid portion is decanted, then evaporated to dryness. The residue after this evaporation is boiled in benzene and filtered.
The solid pot residue remaining after decanting is extracted with hot benzene several times, and these benzene extracts are combined with benzene filtrate. Hexane is added to the cooling benzene and a first crop collected. Partial evaporation gives a second crop. The white solid is alpha-(2-bromophenoxy)acetophenone, m.p. l13.5115.
EXAMPLE 2 Process A, step (2) Polyphosphoric acid (4200 g.) and alpha-(2-bromophenoxyacetophenone (596 g., 2.05 mole) are heated and stirred well at about to internal temperature for four hours. The reaction mixture is then poured into stirred ice and water (about 8 1. total volume) to give a suspension of white solid. The solid is collected and washed with water, cold dilute sodium hydroxide solution and water until the wash is neutral. The solid is recrystalled from hexane to give white crystals of 7-bromo-3-phenylbenzofuran, m.p. 7274.
7-methyl-3-phenylbenzofuran is obtained by cyclizing the required acetophenone at about 80 for one to two hours. The optimum temperature and times vary with other substituents which may be present.
Additional intermediates of this type prepared by the general method of Process A illustrated by Example 1 and 2 include:
7-bromo-3-(4-fluorophenyl)benzofuran, m.p.
7-bromo-3-(3-chlorophenyl)benzofuran, m.p.
7-bromo-3-(4-bromophenyl)benzofuran, m.p.
7-bromo-3-(4-chlorophenyl)benzofuran, m.p.
7-bromo-2-methyl-3-phenylbenzofuran, m.p.
7-chloro-3-phenylbenzofuran, m.p. 75.5-76.5
7-bromo-3-(2-chlorophenyl)benzofuran, m.p.
7-bromo-5-methyl-3-phenylbenzofuran, m.p.
EXAMPLE 3 Process G, steps (1) and (2) Dried magnesium turnings (46.2 g., 1.92 mole), dry tetrahydrofuran (200 ml.) methyl iodide (1 ml.) and a small portion of 7-bromo-3-phenylbenzofuran (total 465.7 g., 1.71 mole) are placed in a dry reactor. After 9 the Grignard reaction is observed to be initiated the remaining benzofuran (diluted with 1 liter of tetrahydrofuran) is added gradually over 1.5 hours at a rate sufficient to maintain moderate reflux. Heating is continued an additional minutes, then the mixture is allowed to cool.
Ethyl pyruvate (400 g., 3.45 mole) in dry tetrahydrofuran (3 1.) is cooled to 50 and the Grignard mixture is added slowly while maintaining the reaction temperature below 35. The mixture is stirred well while allowing it to warm to room temperature over seven hours. The mixture is then heated to its reflux temperature and maintained at reflux for one hour. The mixture is evaporated in vacuo to concentrate it to about 1.5 liters. To this concentrate is added concentrated hydrochloric acid (200 ml.) and 1.5 liters of a mixture of ice and water. The organic phase is separated and the aqueous phase is extracted twice with dichloromethane. The organic phase is combined with these extracts and the solution is washed with saturated sodium chloride solution, then dried and concentrated by evaporation in vacuo to about one liter of an oil which is chiefly ethyl 2-hydroxy-2-[7-(3-phenyl)benzofuranyl]propionate.
This oil is dissolved in three liters of 95% ethanol and 200 ml. of water and the mixture is heated to its reflux temperature. A solution of potassium hydroxide (232 g.) in water (400 ml.) is added over about one hour. The mixture is maintained at its reflux temperature for 3.5 hours. The mixture is then concentrated to about one-half of its volume and the residue is poured into cold water (1.5 1.). The cloudy mixture is extracted with diethyl ether (700 ml. portions).
The aqueous phase is poured into excess dilute hydrochloric acid and the mixture is cooled and acidified with hydrochloric acid. The solid is collected by filtration and washed with several portions of hot water, then with petroleum ether. The white solid is 2- hydroxy-2-[7-(3-phenyl)benzofuranyl]propionic acid, m.p. 1l2.5-ll7.
Another intermediate compound prepared by the general method illustrated by Example 3 is 2-hydroxy- 2-[7-(2-methyl-3-phenyl)benzofuranyHpropionic acid, m.p. l66-l66.5. In general the hydroxy acid may be used directly as obtained for the next step.
EXAMPLE 4 Process G, step (3) Dry 2-hydroxy-2-[7-(3-phenyl)benzofuranyl]propionic acid (337 g., 1.19 mole) in toluene (3 1.) under a nitrogen atmosphere is treated with para-toluenesulfonic acid hydrate (70 g.) and hydroquinone (l g.) while refluxing to azeotropically remove water in a Dean-Start trap. After refluxing for three hours the reaction mixture is cooled, diluted with hexane and cooled by an ice bath. The solid product is collected by filtration washed with petroleum ether, then aqueous ethanol to give 2-[7-(3-phenyl)benzofuranyl]acrylic acid, m.p. l95.5-l98.5.
Additional intermediate compounds prepared by the general method illustrated in Example 4 include:
2-[7-(2-methyl-3-phenyl)benzofuranyl]acrylic acid, m.p. l8018l 2- 4-[3-(4-chlorophenyl)]benzofuranyl acrylic acid, m.p. l75-l8l .2- 7-[3-(2-chlorophenyl)]benzofuranyl acrylic acid,
10 2- 7-[3-(3-chlorophenyl)]benzofuranyl acrylic acid, an oil 2- 7-[3-(4-fluorophenyl)]benzofuranyl acrylic acid,
EXAMPLE 5 Process G, step (4) 2-[7-(3-Phenyl)benzofuranyl]]acrylic acid (40 g., 0.15 mole) is dissolved in warm ethanol (750 ml.) and palladium on charcoal (3 g.) is added. The reduction is carried out using hydrogen gas at 40 psi. initial pressure. The mixture is filtered, then evaporated in vacuo to dryness. The residue is dissolved in benzene (225 ml.) diluted with hexane and cooled. The solid is collected by filtration and again recrystallized from a hexane benzene mixture. The white crystals obtained are 2-[7-( 3-phenyl)benzofuranyl1propionic acid, m.p. l67.5l 68.5.
Analysis: %C %H Calculated for CUHHOQ: 76.7 5.3 Found: 77.1 5.3
EXAMPLE 6 Process F, steps (1) and (2) Dried magnesium turnings (12.2 g., 0.5 mole), dry tetrahydrofuran (50 ml.), methyl iodide (0.5 ml.) and a small sample of 7-bromo-3-(4-fluorophenyl)benzofuran (total 134 g., 0.46 mole) are placed in a dry reactor. After the Grignard reaction is observed to be initiated an additional 500 ml. of tetrahydrofuran is added, then the remaining benzofuran dissolved in tetrahydrofuran (500 ml.) is added over one hour at a rate sufficient to maintain a gentle reflux. The mixture is heated for an additional hour, then heating is stopped.
Paraformaldehyde (41.4 g., 1.38 mole) (dried over phosphorus pentoxide), is depolymerized at about 160 C. while passing the formaldehyde vapor into and over the stirred Grignard reaction mixture. The reaction is exothermic, causing a gentle reflux. Then reaction is complete, the mixture is concentrated to about onethird of its volume, then poured onto ice and water. Diethyl ether (50 ml.) is added, followed by slow addition of concentrated, cold 6N hydrochloric acid (250 ml.). The mixture is extracted with diethyl ether, the extracts are washed with water and saturated sodium chloride solution, dried and evaporated in vacuo to give an oil. The oil is dissolved in absolute ethanol ml.) and concentrated hydrochloric acid (6 ml.) is added. The mixture is heated to reflux temperature and maintained at reflux for 2.5 hours. The mixture is evaporated in vacuo, then the residue is dissolved in diethyl ether, the solution is washed with water and saturated sodium 1 l chloride solution, dried and then concentrated to tan oil crude, 3-(4-fluorophenyl)-7-(hydroxymethyl)benzofuran. Pure product has m.p. 88 89.
An additional intermediate compound of the invention prepared by the general method illustrated by Example 6 is:
7-hydroxymethyl-3-phenylbenzofuran, m.p. 7677 which can be obtained from either 7-bromo-3-phenylbenzofuran or 7-chloro-3-phenylbenzofuran. The crude intermediates can advantageously be used directly in the subsequent steps.
EXAMPLE 7 Process F, step (3) 3-(4-Fluorophenyl)-7-(hydroxymethyl)benzofuran (110 g., 0.45 mole) is dissolved in benzene (225 ml.) and added dropwise to refluxing thionyl chloride (110 ml.). Heating is continued until gas evolution is complete. Excess thionyl chloride and benzene are removed in vacuo, using additional benzene to aid in removing the thionyl chloride. The residue is a brown oil,
7-chloromethyl-3-(4-fluorophenyl)benzofuran.
EXAMPLE 8 Process F, step (4) To a solution of 7-chloromethyl-3-(4-fluorophenyl)- benzofuran (130.3 g., 0.50 mole) in acetone (750 ml) and ethanol (500 ml) is added a solution of sodium cyanide (39.5 g., 0.50 mole) in water (150 ml). The mixture is heated to its reflux for five hours. The mixture is then evaporated in vacuo to concentrate it. The residue is dissolved in dichloromethane, then washed thoroughly with water, dried and concentrated by evaporation in vacuo. The oily residue is recrystallized twice from cyclohexane, then deposited on 70 g. of a silicate material used for elution chromatography and chromatographed on 400 g. of the silicate type column. Elution with hexane, benzenehexane (1:4), (1:1) and (3:2), followed by benzene gives the desired product, 7-cyanomethyl-3-(4-fluorophenyl)benzofuran, in the benzene fractions.
Additional intermediate compounds of the invention prepared according to the general method illustrated by Example 8 include: 7-cyanomethyl-3-phenylbenzofuran, m.p. 1101 1 1 7-cyanomethyl-3-(4-chlorophenyl)benzofuran, m.p. 106120 EXAMPLE 9 Process F, step Potassium hydroxide (85%, 49 g.), 7-cyanomethyl-3- (4-fluorophenyl)benzofuran (48.8 g., 0.194 mole) and 95% ethanol (500 ml.) are mixed and heated at reflux temperature overnight under a nitrogen atmosphere. The mixture is then concentrated by evaporation in vacuo, diluted with water and extracted with diethyl ether. The aqueous phase is filtered, then acidified by the slow addition of hydrochloric acid. The solid is collected by filtration and recrystallized from aqueous ethanol (65%) with treatment with decolorizing charcoal, giving yellow crystals. Another recrystallization from an ethanol-petroleum ether mixture (about 5:1) gives yellow crystals of 3-(4-fluorophenyl)-7-benzofuranacetic acid, m.p. 169-l70.
Analysis: %C %H Calculated for C H FO 71.1 4.1 Found: 71.0 3 .8
Additional intermediate compounds of the invention prepared by the general method illustrated by Example 9 include: 3-phenyl-7-benzofuranacetic acid, m.p. 143l44 3-phenyl-5-benzofuranacetic acid, m.p. 131.5l32 3-phenyl-7-(S-methoxybenzofuran)acetic acid, m.p. 16l162 3-phenyl-6-benzofuranacetic acid, m.p. 142-l44 3-phenyl-7-( S-methylbenzofuran )acetic acid, m.p.. 1 34135 (2-methyl-3-phenylbenzofuran )-6-acetic acid, m .p. 197198 3-(4-methoxyphenyl )-6-benzofuranacetic acid, m.p. 163164 3-(4-methylphenyl)-6-benzofuranacetic acid, m.p. 148.5156 3-(4-fluorophenyl)-6-benzofuranacetic acid, m.p. 15 1l 52 3-(4-chlorophenyl)-7-benzofuranacetic acid, m .p. 169-1 70.5
The 6-acetic acids were prepared by way of the es"- ters, Process E.
EXAMPLE 10 Process L 3-Phenyl-7-benzofuranacetic acid (2.5 g., 0.01 mole) is reduced with hydrogen gas using palladium on charcoal as catalyst and ethanol as solvent in a Brown hydrogenator. After the absorption of hydrogen stops, the reaction mixture is filtered, then the filtrate is evaporated in vacuo to a white solid. Recrystallization from a benzene-hexane mixture gives white crystals of 2,3-
Diethyl malonate (12.7 g., 0.079 mole) is dissolved in ethanol (40 ml.) and treated with sodium hydride (0.079 mole). 7-Chloromethyl-3-phenylbenzofuran (10.0 g., 0.0396 mole) is added and the mixture is heated to its reflux temperature and maintained at reflux for ten hours. Equal volumes of water and diethyl ether are added and the ether extracts are evaporated in vacuo. The residue is dissolved in ethanol and potassium hydroxide (16 g.) is added and the mixture is heated on a steam bath. A yellow solid forms rapidly, but heating is continued overnight. The solution is concentrated by evaporation in vacuo, then equal volumes of water and diethyl ether are added. The ether layer is washed with water, dried then evaporated to dryness. The residue is recrystallized from benzene to give 3- phenyl-7-benzofuranylmethylmalonic acid, m.p. l79180.
3-Phenyl-7-benzofuranylmethylmalonic acid (1.8 g.) is heated to 180 dry, with an oil bath. Gas is evolved for about 10 minutes. The residue is recrystallized from 13 a mixture of benzene-methanol to give 3-[7-(3- phenyl)benzofuranyll-propionic acid, m.p. l6l.5-l62.5.
Analysis: Yr-C %H Calculated for H Q-p 76.7 53 Found: 76.7 5.3
EXAMPLE l2 Process M, step (1) and (2) 7-Methyl-3-phenylbenzofuran is treated with an equimolar amount of bromine in carbon tetrachloride at room temperature until decolorized. The mixture is concentrated to dryness to remove hydrobromic acid and redissolved in carbon tetrachloride. To this solution is added an equimolar amount of N-bromosuccinimide and catalytic amounts (about one gram/mole of benzofuran) of cobalt stearate and tertiary-butyl hydroperoxide. The mixture is heated to reflux temperature and maintained at reflux for two hours while shining a bright floodlight directly upon the reaction mixture. The mixture is cooled, filtered to remove succini mide and concentrated in vacuo to a thick oil which slowly crystallizes on cooling to give 2-bromo-7- bromomethyl-3-phenylbenzofuran, m.p. l35-l38.
EXAMPLE 13 Process M, steps (3) and (4) A solution of 2-bromo-7-bromomethyl-3-phenylbenzofuran (35.6 g., 0.092 mole) dissolved in a minimum amount of dimethyl sulfoxide is added to a solution of sodium syanide (5.9 g., 0.12 mole) in dimethyl sulfoxide (50 ml.) and the mixture is heated at 50 to 60 for two hours. The dark solution is then poured over ice and the solid precipitate is collected by filtration. The product is 2-bromo-7-cyanomethyl-3-phenylbenzofuran.
To a mixture of 50% sodium hydroxide solution (35 ml.) and ethanol (100 ml.) is added 2-bromo-7- cyanomethyl-3-phenylbenzofuran g., 0.032 mole). The mixture is heated to reflux temperature and maintained at reflux for about sixteen hours, then concentrated in vacuo. The residue is diluted with water, then extracted (washed) with diethyl ether. The aqueous layer is acidified with hydrochloric acid, yielding a precipitate which is collected by filtration and recrystallized twice from benzene-hexane mixtures to give 2- Process E, step (3) Ethyl 3-phenyl-5-benzofuranacetate is prepared by cyclization of a-(4-carboethoxymethylphenoxy)acetophenonein five times its weight of polyphosphoric acid at 90 for 30 minutes. Distillation of the crude product gives the desired ester, b.p. ca. 190 C/0.0l mm, m.p. 43-45.
EXAMPLE l5 3-Phenyl-7-benzofuranacetic acid, 6.0 g., is heated for 15 minutes with 3.4 g. of sulfuryl chloride in 50 ml. of benzene then left at room temperature overnight to give 2-chloro-3-phenyl-7-benzofurana.cetic acid which precipitates from the reaction mixture. Recrystallization from benzenehexane gives material of m.pv l50.5-l52.
Analysis: %C %H Calculated for C H CIO 67.1 3.9 Found: 67.3 3.8
In a similar manner one can obtain 2-chloro'3-phenyl-5-benzofuranacetic acid, m.p. -156.5 (benzene) Analysis: %C %H Calculated for C H ClO z 67.] 3.9 Found: 67.] 3.8
EXAMPLE 16 A solution of 1.0 g. of 5-methoxy-3-phenyl-7-benzofuranacetic acid in 5 ml. of acetic acid and 1 ml. of 47% hydriodic acid is heated at reflux for 16 hours to obtain the corresponding S-hydroxy acid. It is isolated by precipitation with water, extraction into ether and then into sodium bicarbonate solution. Recrystallization from benzene gives 5-hydroxy -3-phenyl-7-benzofuranacetic acid, m.p. 197.5199.
Analysis: %C %H Calculated for CMHHO: 7L6 4.5 Found: 71.1 4.6
EXAMPLE 17 By the procedures illustrated in Examples 12 and 6-9 and starting with a-bromo-4-dimethylaminoacetophenone respectively, one obtains: 3-(4-methylthiophenyl)-7-benzofuranacetic acid 3-(4-methylsulfinylphenyl)-7-benzofuranacetic acid 3-(4-methylsulfonylphenyl)-7-benzofuranacetic acid 3-(3-trifluoromethylphenyl)-7-benzofuranacetic acid 3-(4-dimethylaminophenyl)-7-benzofuranacetic acid.
EXAMPLE l8 3-Phenyl-7-benzofuranacetic acid (0.5 g., 2 mmole) in dichloromethane (10 ml.) is treated with thionyl chloride (0.3 ml., 4 mmole). The mixture is heated to its reflux temperature and heated at reflux with stirring for 2.5 hours. Excess thionyl chloride is removed by twice adding benzene and evaporating under vacuum.
lnfrared spectral analysis of the product, 3-phenyl-7- benzofuranacetyl chloride, is'consistent with the assigned structure. lt is used without further purification.
The 3-phenylJ-benzofuranacetyl chloride in diethyl ether (10 ml.) is added to excess diazomethane (8 mmole) in diethyl ether 17 ml.) at 0 over a minute period. The solution is stirred an additional one hour at 0, then evaporated under vacuum. The light yellow solid residue is dissolved in diethyl ether (2 ml.) and triturated with petroleum ether to provide a solid, light yellow product. The purity of the product, 3-pheny1-7- benzofuranacetyldiazomethane, is checked by thin layer chromatography on a silica gel plate and found to be good. lnfrared spectral analysis of the product is consistent with the assigned structure.
A stirred solution of 3-phenyl-7-benzofuranacetyldiazomethane (0.20 g., 0.72 mmole) and 2N sulfuric acid (0.2 ml.) in dioxane (3 ml.) is heated at 60 to 65 for 20 minutes. The mixture is allowed to cool, then the white precipitate is separated by filtration, washed with water and recrystallized from ethanol to give hydroxy- A solution of 3-(4-fluorophenyl)-7-benzofuranacetic acid (4.0 g., 14.8 mmole) in dichloromethane (100 ml.) is treated with thionyl chloride (2.2 ml., 30 mmole) and heated to its reflux temperature and maintained at reflux for three hours. The mixture is concentrated to an oil by evaporation under vacuum, dissolved in benzene (30 ml.) and evaporated under vacuum. The infrared spectrum of the product, 3-(4-fluorophenyl)-7-benzofuranacetyl chloride, is consistent with the assigned structure.
The acid chloride (4.3 g., 14.8 mmole) is dissolved in diethyl ether (80 ml.) and added dropwise to a cold (about 0 C.) solution of diazomethane (45 mmole) in diethyl ether (100 ml.) over a period of 30 minutes. The solution is stirred at 0 C. for two hours, then evaporated under vacuum. The residue is a light yellow solid, 3-(4-fluorophenyl)-7-benzofuranacetyldiazomethane. The infrared spectrum of the product is consistent with the assigned structure. The substituted diazomethane is then dissolved in dioxane (80 ml.) and treated with 0.1N aqueous perchloric acid (40 ml.) while stirring at 6065 for 1.5 hours.'The mixture is evaporated under vacuum, then water is added and the mixture is again evaporated under vacuum. The white solid precipitate is separated by filtration and washed with water and petroleum ether. The solid is dissolved in diethyl ether and the solution is washed thrice with 50 ml. portions of 1N aqueous sodium carbonate and thrice with 50 ml. portions of saturated sodium chloride solution, then dried over anhydrous magnesium sulfate. The solution is filtered, then the solvent is removed by evaporation :undervacuumfThe residue is recrystallized from diethyl ether to provide pale yellow plates of 3-(4-fluoro phenyl )-7ben;ofuranmethyl hydroxymethyl ketone, 'mq 100-101.
EXAMPLE 20 A stirred solution of 2-[7-(3-phenyl)benzofuranyl)]- propionic acid (5.0 g., 18.8 mmole), dichloromethane (100 ml.) and thionylchloride (3 m1.) is heated to its reflux temperature and maintained at reflux for one day. The solution is evaporated under vacuum, the residue is twice dissolved in benzene and evaporated. The infrared spectrum ofthe product, 2- [7-(3-phenyl)benzofuranyl)]propionyl chloride (an oil), is consistent with the assigned structure.
The acid chloride is dissolved in diethyl ether (50 m1.) and added dropwise to a stirred cold (about 0) solution of diazomethane (57 mmoles) in diethyl ether (125 ml.). After the addition the mixture is stirred for 0.5 hour at 0 and 0.5 hour at ambient temperature. The mixture is then evaporated under vacuum to alight yellow oil. The infrared spectrum of the product, 2-[7- (3-phenyl)benzofuranyl)]propionyldiazomethane, is consistent with the assigned structure.
The substituted diazomethane is then dissolved in dioxane (100 m1.) and treated with 0.5N aqueous perchloric acid (50 m1.)while stirring at about 65 C. for 0.75 hour. The solution is evaporated under vacuum, and the residue is extracted with diethyl ether. The ether extracts are washed thrice with ml. portions of 1N aqueous sodium carbonate, then the ether solution is filtered, then evaporated under vacuum to provide a light yellow oil. The oil is chromatographed on a silica gel column, eluting with hexane, 50:50 hexane:- chloroform, chloroform and 50:50 chloroformtmethanol. Infrared spectral analysis of the fractions obtained shows that the later fractions are chiefly the desired product. Two recrystallizations from ethanol:petroleum ether mixtures give white solid product, hy-
droxymethyl 2-[ 7-( 3-phenyl )benzofuranyl ]ethylketone, m.p. 8l85.
Analysis: %C %H Calculated for c,,,n,.,o,,; 77.29 6.45 Found: 77.65 6.00
Compounds'of the invention prepared according to the methods specifically illustrated in Examples l8, l9 and 20 are shown in the table which includes Figures 17-34.
What is claimed is:
1. A compound of the formula Y o R 0 R gbhg Cbn Oli A'r u R wherein R is hydrogen, lower alltylor 'lialog en', provided that when R is halogengthegroup l i 2. A compound according to claim 1 wherein R is hydrogen.
3. A compound according to claim 1 wherein R is halogen and the group is in the 7 position.
4. A compound according to claim 1 wherein R is hydrogen or methyl and R is hydrogen.
5. A compound according to claim 1 wherein Ar is halo-substituted phenyl.
6. A compound of the formula wherein R is hydrogen or methyl and Ar is phenyl or halogen-substituted phenyl.
7. Hydroxymethyl 3-phenyl-7-benzofuranmethylketone according to claim 6.
8. 3-(4-Fluor0phenyl)-7-benzofuranmethyl hydroxymethyl ketone according to claim 6.
9. Hydroxymethyl 2-[7-(3-phenyl)benzofuranyl]ethylketone according to claim 6.
. Page 1 of 2 UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION PATENT N0. 3,917,65h DATED November A, 1975 lN\ ENTOR(S) Francis J. Petracek It is certified that error appears'in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
Title should be "Anti-Inflammatory Substituted Benzofurans- Column 8, line 2: Ihe first "and" should read are-- Column 9, line 55: "Start" should read -,Stark-- Column 9, line 65: "2-. L-[3( L-ch'lorophenyl) ]benzofuranyl acrylic" should read --2-{ +[3-(M-chlorophenyl) ]ben'zofuranyl acrylic---- Column 9, line 672' "2- 7-[3-(2-chlorophenyl) ]benzofuranyl acrylic" should read -2-{7-[3-(E-chlorophenyl)-]benzofuranyl} acrylic- 5 Column l0 line 1: "2- 7- [3-(3-chlorophenyl) ]benzofuranyl v acrylic should read --2-{7-[3-(3-chlorophenyl) ]benzo'iuranyl acrylic-'- Column l0 line 3: "2- 7- [3- -L-fluorophenyl) jbenzofuranyl acrylic should read --2- 7-[3(h fluorophenyl)]benzofuranyl} acrylic-- Column lO,'lines 30132, 3n, and 36: Insert before the "7" and insert after the "benzofuranyl" Column 12, line 8: "142" should read "l -L3 Page 2 of 2 UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION PATENT N0. 3,9l7, 5 DATED November i, 1975 *iNvENmms) Francis J. Petracek.
it is certified that error appears in the above-identified patent and that said Letters Patent are'hereby corrected as shown below: I
Claim 1, first formula not legible and should read:
2 -O R,- O
R (:(CR 3011 OH" 2 Ar H R I v Signed and. Scaled this Twenty-fourth 7 August 1976 [SEAL] Arrest:
RUTH c. MASON c. MARSHALL DANN off Commissioner ofParems and Trademarks

Claims (9)

1. A COMPOUND OF THE FORMULA
2. A compound according to claim 1 wherein R1 is hydrogen.
3. A compound according to claim 1 wherein R1 is halogen and the group
4. A compound according to claim 1 wherein R4 is hydrogen or methyl and R5 is hydrogen.
5. A compound according to claim 1 wherein Ar is halo-substituted phenyl.
6. A compound of the formula
7. Hydroxymethyl 3-phenyl-7-benzofuranmethylketone according to claim 6.
8. 3-(4-Fluorophenyl)-7-benzofuranmethyl hydroxymethyl ketone according to claim 6.
9. Hydroxymethyl 2-(7-(3-phenyl)benzofuranyl)ethylketone according to claim 6.
US368174A 1973-06-08 1973-06-08 Anti-inflammatory substituted benzofuran Expired - Lifetime US3917654A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US368174A US3917654A (en) 1973-06-08 1973-06-08 Anti-inflammatory substituted benzofuran

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US368174A US3917654A (en) 1973-06-08 1973-06-08 Anti-inflammatory substituted benzofuran

Publications (1)

Publication Number Publication Date
US3917654A true US3917654A (en) 1975-11-04

Family

ID=23450150

Family Applications (1)

Application Number Title Priority Date Filing Date
US368174A Expired - Lifetime US3917654A (en) 1973-06-08 1973-06-08 Anti-inflammatory substituted benzofuran

Country Status (1)

Country Link
US (1) US3917654A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4124605A (en) * 1975-09-24 1978-11-07 Riker Laboratories, Inc. 2-Nitro or 2-bromo-(3-cyanomethylphenyl)benzofurans
US4208336A (en) * 1975-09-24 1980-06-17 Riker Laboratories, Inc. Certain 3-bromomethylphenyl-2-bromo-benzofurans
US4562267A (en) * 1980-07-28 1985-12-31 Pfizer Inc. Intermediates of hypoglycemic 5-substituted oxazolidine-2,4-diones
FR2744452A1 (en) * 1996-02-06 1997-08-08 Cird Galderma HETEROCYCLIC BIARYLATED COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM AND USES
WO1999006388A2 (en) * 1997-07-31 1999-02-11 Proteome Sciences Plc. Pharmaceutical compounds isolated from aristolochia taliscana
US20080143144A1 (en) * 2006-12-14 2008-06-19 Ford Global Technologies, Llc Structural stability device for automotive frame members

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lundquist et al., Chem. Abstracts, (1972), Vol. 87, 47537 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4124605A (en) * 1975-09-24 1978-11-07 Riker Laboratories, Inc. 2-Nitro or 2-bromo-(3-cyanomethylphenyl)benzofurans
US4208336A (en) * 1975-09-24 1980-06-17 Riker Laboratories, Inc. Certain 3-bromomethylphenyl-2-bromo-benzofurans
US4562267A (en) * 1980-07-28 1985-12-31 Pfizer Inc. Intermediates of hypoglycemic 5-substituted oxazolidine-2,4-diones
FR2744452A1 (en) * 1996-02-06 1997-08-08 Cird Galderma HETEROCYCLIC BIARYLATED COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM AND USES
WO1997029100A1 (en) * 1996-02-06 1997-08-14 Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) Heterocyclic diaryl compounds, pharmaceutical and cosmetic compositions containing same, and uses thereof
US5981776A (en) * 1996-02-06 1999-11-09 Centre International De Recherches Dermatologiques Galderma Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
US20040162339A1 (en) * 1996-02-06 2004-08-19 Philippe Diaz Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
WO1999006388A2 (en) * 1997-07-31 1999-02-11 Proteome Sciences Plc. Pharmaceutical compounds isolated from aristolochia taliscana
WO1999006388A3 (en) * 1997-07-31 1999-04-22 Electrophoretics International Pharmaceutical compounds isolated from aristolochia taliscana
US20080143144A1 (en) * 2006-12-14 2008-06-19 Ford Global Technologies, Llc Structural stability device for automotive frame members

Similar Documents

Publication Publication Date Title
US3862134A (en) Phenylbenzofuran acrylic acid compounds and salts and esters thereof
US4251528A (en) Phthalazin-4-ylacetic acid derivatives
US3420851A (en) Novel dibenzoxepines
IL25317A (en) Bis-(substituted phenoxy)-and bis-(2-carboxy-chromonyloxy)compounds,their preparation and use
Castaldi et al. Tartaric acid, an efficient chiral auxiliary: new asymmetric synthesis of 2-alkyl-2-arylacetic acids
US3849493A (en) D-ring substituted 6-deoxytetracyclines
GB1586152A (en) Mevalonolactone derivatives their use and preparation
US3519652A (en) Bis-chromonyl compounds
US4548948A (en) Anti-inflammatory and analgesic benzothiophene and benzafuran derivatives, compositions, and method of use therefor
US3917654A (en) Anti-inflammatory substituted benzofuran
US3829453A (en) Octahydroanthracene-2-aminoacetic acids and esters and mixed anhydrides thereof
Abe et al. Santonin. III. 1 The Total Synthesis of Santonin2
Fieser et al. A Synthesis of 4, 10-Ace-1, 2-benzanthracene Utilizing Δ4-Tetrahydrophthalic Anhydride
US3772363A (en) 3,4,10-trioxo octahydroanthracene-2-aminoacetic acids and derivatives thereof
Matsunaga et al. Cylindol A, a novel biphenyl ether with 5-lipoxygenase inhibitory activity, and a related compound from Imperata cylindrica
IE47299B1 (en) 1,2-benzisoxazoloxyacetic acid and related compounds
US3308121A (en) 3-morpholinones, thiones and 5, 6 oxazines
US4153791A (en) 3-Carboxy-4 hydroxyphenylthioacetmorpholide
US4623728A (en) Intermediates for 1,3-disubstituted piperidine compounds as neuroleptic agents
US4593037A (en) 1,3-disubstituted piperidine compounds as neuroleptic agents
US4013692A (en) Certain 3-phenyl-benzofuran lower alkanoic acids and esters thereof
US3923900A (en) 1-(6-Methoxy-2-naphthyl)ethyl hydroxymethylketone
US4456612A (en) Benzisoxazole carboxylic acids
US4097582A (en) 6',2-(2'-Arylchromonyl) propionic acids, and analgesic and anti-inflammatory derivatives thereof
Case et al. Substituted 1, 10-Phenanthrolines. XIII. The Synthesis of New 4-Mono-and 4, 7-Dialkyl-and-aryl-1, 10-phenanthrolines1